Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression
Mov Disord
.
2021 Oct;36(10):2444-2446.
doi: 10.1002/mds.28715.
Epub 2021 Jul 8.
Authors
Luis Concha-Marambio
1
,
Carly M Farris
1
,
Bret Holguin
1
,
Yihua Ma
1
,
John Seibyl
2
,
Marco J Russo
3
,
Un J Kang
3
,
Samantha J Hutten
4
,
Kalpana Merchant
5
,
Mohammad Shahnawaz
6
,
Claudio Soto
1
6
Affiliations
1
R&D Unit, Amprion Inc., San Diego, California, 92121, USA.
2
Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA.
3
Department of Neurology, Neuroscience Institute, NYU Grossman School of Medicine, New York, New York, USA.
4
The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
5
Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
6
Mitchell Center for Alzheimer's Disease and Related Brain Disorders, University of Texas McGovern Medical School, Houston, Texas, USA.
PMID:
34236720
PMCID:
PMC8530949
DOI:
10.1002/mds.28715
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
Dopamine
Humans
Parkinson Disease* / diagnosis
Parkinson Disease* / genetics
Substances
Dopamine
Grants and funding
R01 AG061069/AG/NIA NIH HHS/United States
RF1 AG055053/AG/NIA NIH HHS/United States